10X RIPA Lysis Buffer
10X RIPA Lysis Buffer
RIPA used for western blot
RIPA used for western blot
Datasheet is currently unavailable. Try again or CONTACT US
Datasheet

10X RIPA Lysis Buffer

5 References
MB-077-0015 MB-077-0050
15 mL 50 mL
Liquid (sterile filtered) Liquid (sterile filtered)
WB, ChIP, IP, Other
$179.00 /Per Item
$535.00 /Per Item
15 mL $179.00
50 mL $535.00
In stock
Ships next business day
In stock
Ships next business day
Request a Quote
Bulk Orders Bulk Orders
Shipping info:

$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.

Product Details

10X RIPA Lysis Buffer - MB-077-0015
10X RIPA Lysis Buffer, RIPA (Radio-Immunoprecipitation Assay) Lysis Buffer

Target Details

This product was aseptically filtered through a Millipore 0.22 micron filter into clean, pre-sterilized containers. The product was tested on trypticase soy agar for 24 hours, 48 hours and 72 hours and was found to be negative for bacteria.

Application Details

ChIP, IP, WB
Other  - View References
This product is 10X concentrated stock solution. Dilute to 1X prior to use. 1X RIPA Lysis Buffer is intended for the extraction of cellular proteins for the efficient lysis of cells and solubilization of protein, while minimizing protein degradation and maintaining protein immunoreactivity and biological activity. We recommend using 1.0 ml of RIPA Lysis Buffer to lyse 0.5 to 5 x 10E7 adherent mammalian cells. This buffer contains ionic detergents and may not be suitable for kinase enzymes, if these enzymes are easily denatured. Do not add phosphatase inhibitors when preparing lysates for phosphatase assays. 1X RIPA lysis buffer consists of 50 mM Tris HCl, 150 mM NaCl, 1.0% (v/v) IGEPAL® CA-630, 0.5% (w/v) Sodium Deoxycholate, 1.0 mM EDTA, 0.1% (w/v) SDS and 0.01% (w/v) sodium azide at a pH  of 7.4.  This buffer was meticulously prepared using ultra pure reagents dissolved in highly polished pharmaceutical grade deionized water. Protease and phosphatase inhibitors are recommended but not included in product composition. Recommended final concentrations of protease inhibitors: 1.0 mM Phenylmethylsulfonyl fluoride (PMSF) 10 µM Leupeptin 0.1 µM Aprotinin 1.0 µM Pepstatin Recommended final concentrations of phosphatase inhibitors: 1.0 mM Na3VO4 1.0 mM NaF

Formulation

10X
See application note.
0.01% (w/v) Sodium Azide
None

Shipping & Handling

Ambient
Store container at room temperature (18° to 26° C) prior to opening. Protect from light (store in the dark).
Expiration date is six (6) months from date of receipt.
RIPA (Radio-Immunoprecipitation Assay) Lysis Buffer enables rapid, efficient cell lysis and solubilization of proteins from both adherent and suspension cultured mammalian cells. It has long been a widely used lysis and wash buffer for small-scale affinity pull-down applications, such as immunoprecipitation, since most antibodies and protein antigens are not adversely affected by the components of this buffer. In addition, RIPA Lysis Buffer minimizes non-specific protein-binding interactions to keep background low, while allowing most specific interactions to occur, enabling studies of relevant protein-protein interactions.  The following RIPA Lysis Buffer components have the following effects: Tris-HCl is a buffering agent prevents protein denaturation, NaCl is a salt that prevents non-specific protein aggregation, IGEPAL is a non-ionic detergent to extract proteins; Na-deoxycholate and SDS are ionic detergents to extract proteins; and sodium azide is a bacteriostatic agent added to retard bacterial growth.  RIPA Lysis Buffer is supplied as a ready-to-use solution that requires no preparation. We suggest that the user add protease and phosphatase inhibitors not included with this product prior to use.
(). Down-regulating miR-217-5p Protects Cardiomyocytes against Ischemia/Reperfusion Injury by Restoring Mitochondrial Function via Targeting SIRT1. Inflammation.
Applications
Other
(). Pathogenetic implications of early growth response 1 in Ewing sarcoma. Pathology.
Applications
WB, IB, PCA
(). Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth. Biochem Pharmacol.
Applications
Cell Lysis
(). Chronic intermittent low-level transcutaneous electrical stimulation of auricular branch of vagus nerve improves left ventricular remodeling in conscious dogs with healed myocardial infarction. Circ Heart Fail.
Applications
WB, IB, PCA
(). Early short-term vagal nerve stimulation attenuates cardiac remodeling after reperfused myocardial infarction. J Card Fail.
Applications
Other

Invalid lot number

If you need help finding your CoA, contact us

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

Related Resources

Assay Substrate Selection Guide

Articles
View Article

Blocking Buffer Selection Guide

Articles
View Article

Streptavidin: Properties and Applications

Articles
View Article